Souhaitez-vous accéder aux communiqués récents ?

Live video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today that it will...

As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.

OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical...

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million. Reference is made to the stock exchange announcement published on 27 January 2026...

OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

HOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells...

This high unmet need has drawn interest to novel mechanisms of action — including Propanc Biopharma’s pancreatic proenzyme formulation known as PRP.

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE...

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study...